Recently incorporated into the list of procedures by the National Health Agency (ANS), Lenvima (lenvatinib mesylate ) is the new medication for thyroid cancer intended for patients who have already undergone radioiodine therapy and were unsuccessful
a theoretical modeling of physics helped a group of researchers in designing a new therapeutic approach that reduces the expression of a network of tumor metastases signals. The strategy, which uses low doses of multiple drugs, reduced the compensato